Eikon Therapeutics: Results Of Operations And Financial Condition, Financial Statements And Exhibits
— We have everything you need: full data on over 900 000 bonds, 80 000 stocks, 116 000 ETF & Funds; powerful bond screener; over 350 pricing sources among stock exchanges & OTC market; ratings & ...
Investing.com - Mizuho reiterated an Outperform rating and $26.00 price target on Eikon Therapeutics Inc. (NASDAQ:EIKN) following the company’s fiscal year 2025 earnings report and pipeline update.The ...
Closed upsized initial public offering in February 2026, raising $381 million in gross proceeds Completed enrollment of the TeLuRide-005 Phase 2 trial of EIK1001 in first-line treatment of stage 4 non ...
MILLBRAE, Calif., March 30, 2026 (GLOBE NEWSWIRE)-- Eikon Therapeutics, Inc. (Nasdaq: EIKN) (“Eikon”), a late-stage clinical biopharmaceutical company dedicated to developing innovative medicines to ...
Closed upsized initial public offering in February 2026, raising $381 million in gross proceeds Completed enrollment of the TeLuRide-005 Phase 2 trial of EIK1001 in first-line treatment of stage 4 non ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results